Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027488 · ClinicalTrials.gov registry record · Phase 1
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07027488 is a Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 169-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07027488, a Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) in participants with recurrent locally advanced or metastatic melanoma and other immune-responsive solid tumors. Immune-responsive solid tumors are defined as those for which immune checkpoint inhibitors form part of the standard-of-care therapy.
Conditions Studied
Interventions
- DRUG AB821
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07027488
The ClinicalTrials.gov registry entry for NCT07027488 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (70% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Melanoma appearing as the primary indexed condition, and to 1 intervention - of which AB821 is the first listed.
NCT07027488 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07027488 about?
NCT07027488 is a clinical study titled "AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors". This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) in participants with recurrent locally ad...
What is the current status of trial NCT07027488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-08-05. Estimated completion is 2027-08.
What conditions does trial NCT07027488 study?
This clinical trial studies the following conditions: Advanced Melanoma, Advanced Melanoma and Normal or Impaired.
What interventions are being tested in trial NCT07027488?
The interventions under investigation include: AB821 (DRUG).
Who is sponsoring clinical trial NCT07027488?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027488 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
Naltrexone and Propranolol Combined With Immunotherapy
RECRUITING · Phase 1
-
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
RECRUITING · Phase 1
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
RECRUITING · Phase 1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Melanoma
All registered trials for this condition
Advanced Melanoma and Normal or Impaired
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.